Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects

Abstract

BackgroundTo prospectively analyze the efficacy of uromune® in the prevention of uncomplicated recurrent urinary tract infections at 3 and 6 months, and according to gender and menopause.MethodsFrom September 2011 to December 2017 uromune® was administered sublingually every 24 h along 3 months to 784 patients with history of three or more uncomplicated urinary tract infections in the 12 months prior to the first visit.The variables analyzed with statistical package system for science version 15.0 were age, gender, number of urinary tract infections with positive urine culture in the first consultation, and 3 and 6 months after the end of treatment.The results with positive urine culture were registered at 3 and 6 months after the end of the treatment according to gender and also in the menopausal group with respect to pre-menopausal women.ResultsMean age was 73.5 years. 82.7% were women and 94.3% menopausal.The number of episodes of urinary tract infections in the 12 months prior to uromune® were 3 in 37.2%, 4 in 28.1%, 5 in 19.5%, 6 in 9.6%, 7 in 4%, 8 in 1.4%, 9 in 0.1% and 10 in 0.1%.Three months after uromune® 44.1% had 0 urinary tract infections and 27.6% had 1. After 6 months the results were 0 urinary tract infections in 32.3% and 1 in 32.4%.Women had 0 urinary tract infections after 3 months in 45.4% and 1 in 28.5%. At 6 months the female had 0 episodes in 32.7% and 1 in 33.2%.Menopausal women had 0 urinary tract infections at 3 months in 46.5% and 1 in 28% and at 6 months scored 0 episodes in 33.6% and 1 in 32.9%.ConclusionsUromune® was highly effective to reduce the number of episodes of urinary tract infections at three and six months of follow-up. Uromune® reduced the number of episodes to zero or one in 71.7 and 64.7% at three and six months with minimal side effects.The best results were observed in women over 50 years old.Sublingual immunoprophylaxis with uromune® could be the treatment of first choice in the prevention of uncomplicated recurrent urinary tract infections according to the sample analyzed.

A Combination of Polybacterial MV140 and Candida albicans V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections

“…MV140 (Uromune) is a sublingual vaccine for RUTIs prophylaxis that is able to prime human DCs with the capacity to induce Th1-, Th17-, and IL-10-producing T cells (26). Clinical studies have demonstrated that MV140 significantly prevents RUTIs in 80% to 90% of individuals during the year following vaccination (39)(40)(41)(42)(43). The reported clinical benefits indicate that sublingual administration of MV140 also reduces the overuse of antibiotics, which not only might reduce the increase in antibiotic-resistances (40), but also avoid microbiota disruption (1,7,(9)(10)(11)(12).…”

“…This sublingual vaccine is composed of bacteria causing the majority of RUTIs in Europe: 75% Gram-negative bacteria (25% Escherichia coli, 25% Proteus vulgaris and 25% Klebsiella pneumoniae) and 25% Gram-positive bacteria (Enterococcus faecalis) (26). Clinical data showed that MV140 significantly reduced the infection rates in patients suffering from RUTIs (39)(40)(41)(42)(43). MV140 acts directly on human DCs promoting maturation and activation through mechanisms depending on Syk-and MyD88mediated signaling pathways, supporting the involvement of C-type lectin receptors (CLRs) and toll-like receptors (TLRs).…”

Antibiotic Susceptibility and Molecular Characterization of Uropathogenic Escherichia coli Associated with Community-Acquired Urinary Tract Infections in Urban and Rural Settings in South Africa

“…Also, a small number of pregnant women with UTIs (14%) was ecorded in the present study and this could be explained by the fact that antenatal clinics functioned separately from the primary healthcare clinics at the CHCs investigated. UTIs were most common in the 18 to 28-year age group which could be due to higher sexual activities, as it is reported that highest sexual activities was observed in women between the ages of 18 and 39 [ 26 ]. Frequent intercourse has been listed among risk factors for developing a UTI [ 27 ], while an association between frequency of intercourse and the chances of developing a UTI has been demonstrated [ 28 , 29 ].…”

Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections

“…A prospective observational study showed that 59 out of 75 women (78%) which received 3 months of Uromune ® treatment as a sub-lingual spray once a day, had no new UTIs during both the treatment and the one year of follow-up period ( Yang and Foley, 2018 ). Another recent lager prospective study showed that 65% of 784 women had 0 or 1 UTI after 6 months of daily sub-lingual administration of Uromune ® ( Ramirez Sevilla et al, 2019 ).…”